吲哚菁绿15分钟滞留率对肝癌合并门静脉高压症患者经颈静脉肝内门体分流术后肝性脑病发生风险的预测价值

王重; 岳振东; 赵洪伟; 王磊; 范振华; 吴一凡; 董成宾; 张裕; 刘福全

doi:10.3969/j.issn.1001-5256.2020.09.017

吲哚菁绿15分钟滞留率对肝癌合并门静脉高压症患者经颈静脉肝内门体分流术后肝性脑病发生风险的预测价值

DOI: 10.3969/j.issn.1001-5256.2020.09.017

首都医科大学附属北京世纪坛医院介入治疗科

基金项目:

首都卫生发展科研专项(2018-1-2081)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1653
- HTML全文浏览量: 42
- PDF下载量: 118
- 被引次数: 18
出版历程
- 出版日期: 2020-09-20

Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University

Research funding:

摘要

摘要:
目的分析吲哚菁绿15 min滞留率（ICG-R15）、Child-Turcotte-Pugh（CTP）分级和终末期肝病模型（MELD）评分预测肝癌合并门静脉高压症患者经颈静脉肝内门体分流术（TIPS）后肝性脑病（HE）发生的临床价值。方法回顾性分析2015年1月-2017年6月在首都医科大学附属北京世纪坛医院经TIPS治疗的95例肝癌合并门静脉高压症患者的临床资料,根据TIPS术后是否发生HE分为HE组（n=24）和非HE组（n=71）;所有患者术前均进行ICG-R15测定、CTP分级、MELD评分。计量资料满足正态分布的2组间比较采用t检验,不满足正态分布的2组间比较采用Mann-Whitney U检验,计数资料2组间比较采用χ2检验和Fisher精确检验。采用单因素、多因素logistic回归分析TIPS术后HE发生相关的危险因素。采用受试者工作特征曲线（ROC曲线）分析比较ICG-R15、CTP和MELD评分对HE发生的预测价值。结果 TIPS术后12个月内HE发生率为25.2%（24/95）。logistic单因素分析显示,TIPS术后HE发生的相关因素有支架位置（P=0.02...
- 肝肿瘤 /
- 吲哚花菁绿 /
- 高血压,门静脉 /
- 门体分流术,经颈静脉肝内 /
- 肝性脑病
Abstract:
Objective To investigate the clinical value of indocyanine green retention rate at 15 minutes( ICG-R15),Child-Turcotte-Pugh( CTP) class,and Model for End-Stage Liver Disease( MELD) score in predicting post-transjugular intrahepatic portosystemic shunt( TIPS) hepatic encephalopathy( HE) in liver cancer patients with portal hypertension. Methods A retrospective analysis was performed for the clinical data of 95 liver cancer patients with portal hypertension who underwent TIPS in Department of Interventional Therapy in Beijing Shijitan Hospital from January 2015 to June 2017,and according to the presence or absence of HE after TIPS,they were divided into HE group with 24 patients and non-HE group with 71 patients. ICG-R15,CTP class,and MELD score were determined for all patients before surgery. The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test and the Fisher's exact test were used for comparison of categorical data between two groups. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for HE after TIPS,and the receiver operating characteristic( ROC) curve was used to analyze the value of ICG-R15,CTP class,and MELD score in predicting HE. Results The incidence rate of HE was 25. 2%( 24/95) within 12 months after TIPS. The univariate analysis showed that stent location( P = 0. 021),ICG-R15( P = 0. 005),and CTP class( P = 0. 040) were associated with HE after TIPS. The multivariate analysis showed that stent located in the right portal vein( OR = 3. 373,95% CI: 2. 346 ～ 5. 103,P = 0. 010) and ICG-R15 > 30%( OR = 2. 107,95% CI: 1. 331 ～ 3. 212,P = 0. 036) were independent risk factors for HE after TIPS in liver cancer patients with portal hypertension. The ROC curve analysis showed that ICG-R15,MELD score,and CTP class had an area under the ROC curve of 0. 659,0. 638,and 0. 621,respectively,in predicting HE after TIPS. Conclusion ICG-R15 has a certain clinical value in predicting HE after TIPS in liver cancer patients with portal hypertension.
- liver neoplasms /
- indocyanine green /
- hypertension,portal /
- portasystemic shunt,transjugular intrahepatic /
- hepatic encephalopathy

HTML全文

参考文献(19)

[1] Cancer minimally invasive therapy professional committee of china cancer association,Asian society for tumor ablation.Minimally invasive and multi-disciplinary comprehensive diagnosis and treatment of hepatocellular carcinoma:2018guangzhou consensus[J]. J Clin Hepatol,2019,35(10):2176-2184.(in Chinese)亚太影像引导下肿瘤微创治疗协会，中国抗癌协会肿瘤微创治疗专业委员会，亚洲肿瘤消融学会．肝细胞癌微创与多学科综合诊疗———2018广州共识[J]．临床肝胆病杂志，2019,35(10):2176-2184.

[2] SANKAR K,MOORE CM. Transjugular intrahepatic portosystemic shunts[J]. JAMA,2017,317(8):880.

[3] ROWLEY MW,CHOI M,CHEN S,et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt:Risk factors and outcomes with revision[J].Cardiovasc Intervent Radiol,2018,41(11):1765-1772.

[4] KRAGLUND F,JEPSEN P,AMANAVICIUS N,et al. Longterm effects and complications of the transjugular intrahepatic portosystemic shunt:A single-centre experience[J]. Scand J Gastroenterol,2019,54(7):899-904.

[5] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-The Albumin-Indocyanine Green Evaluation(ALICE)grade[J]. PLo S One,2016,11(7):e0159530.

[6] WANG YY,ZHAO XH,MA L,et al. Comparison of the ability of Child-Pugh score,MELD score,and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,118(3):440-445.

[7] AZUMI M,SUDA T,TERAI S,et al. Prognostic impact of indocyanine green plasma disappearance rate in hepatocellular carcinoma patients after radiofrequency ablation:A prognostic nomogram study[J]. Intern Med,2017,56(9):1001-1007.

[8] SONG P,INAGAKI Y,WANG Z,et al. High levels of gammaglutamyl transferase and indocyanine green retention rate at 15min as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma[J]. Medicine(Baltimore),2015,94(21):e810.

[9] LLOVET JM,ZUCMAN-ROSSI J,PIKARSKY E,et al. Hepatocellular carcinoma[J]Nat Rev Dis Primers,2016,2:16018.

[10] International group,Chinese Society of Radiology,Chinese medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228.

[11] ZOU H,YANG X,LI Q L,et al. A comparative study of albumin-bilirubin score with child-pugh score,model for endstage liver disease score and indocyanine green r15 in predicting posthepatectomy liver failure for hepatocellular carcinoma patients[J]. Dig Dis,2018,36(3):236-243.

[12] SIA D,VILLANUEVALL A,FRIEDMAN SL,et al. Liver cancer cell of origin,molecular class,and effects on patient prognosis[J]. Gastroenterology,2017,152(4):745-761.

[13] FERLAY J,SOERJOMATARM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.

[14] MARENOGO A,ROSSO C,BUGIANESI E. Liver cancer:Connections with obesity,fatty liver,and cirrhosis[J]. Annu Rev Med,2016,67:103-117.

[15] MONTAGNESE S,RUSSO FP,AMODIO P,et al. Hepatic encephalopathy 2018:A clinical practice guideline by the Italian Association for the Study of the Liver(AISF)[J]. Dig Liver Dis,2019,51(2):190-205.

[16] HIWATASHIL K,UENO S,SAKODA M,et al. The evaluation of liver function and surgical influence by ICGR15 after chemotherapy for colorectal liver metastases[J]. J Cancer,2016,7(5):595-599.

[17] HE F,DAI S,XIAO Z,et al. Pathological predictors of shunt stenosis and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Biomed Res Int,2016,2016:3681731.

[18] LUO SH,CHU JG,HUANG H,et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J].World J Gastroenterol,2019,25(9):1088-1099.

[19] KAPLAN DE,DAI F,AYTAMAN A,et al. Development and performance of an algorithm to estimate the child-turcottepugh score from a national electronic healthcare database[J]. Clin Gastroenterol Hepatol,2015,13(13):2333-2341. e1-6.

施引文献

期刊类型引用(17)

1.	郭堑，农村立，韦秋芳. 慢性乙型肝炎肝纤维化患者血清Copeptin和PCT表达水平及其临床价值研究. 现代检验医学杂志. 2023(02): 112-117+189 . 百度学术
2.	李初谊，王俊科，李斌，温雪，魏晓静，于晓辉. 血浆置换对慢加急性肝衰竭辅助治疗的效果评价. 海南医学院学报. 2022(16): 1228-1231 . 百度学术
3.	王鑫，张国民，牛兴杰，李萍，张冰. 外周血CD14~+CD16~+单核细胞亚群在肝衰竭继发感染患者中的检测价值. 中国免疫学杂志. 2020(09): 1124-1127+1130 . 百度学术
4.	姜曼蕾，许飞，胡江玲，罗嘉裕，罗方云. IL-6、CRP、PCT和内毒素预判肝衰竭合并细菌感染风险中的临床价值. 中华医院感染学杂志. 2020(20): 3062-3065 . 百度学术
5.	张国民，王鑫，韩智炜，牛兴杰，刘志慧，崔凤梅. 降钙素原、白细胞介素6、sCD14、CD64检测在肝功能衰竭患者诊治中的临床研究. 中国现代医学杂志. 2019(03): 47-51 . 百度学术
6.	江艳霞，骆小燕，骆旭航，龚安安，孙爱华. 血清降钙素原在胆管炎危重度早期评估中的价值研究. 中国卫生检验杂志. 2019(04): 462-463+468 . 百度学术
7.	张国民，韩智炜，牛兴杰，刘志慧，王鑫. IL-6、CD14、CD64检测在感染所致肝衰竭患者中意义. 现代医学. 2019(02): 137-140 . 百度学术
8.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 . 百度学术
9.	杨丽霞，张伦理，赖玲玲，方铭. 腹水中肝素结合蛋白及降钙素原对肝硬化腹水伴自发性细菌性腹膜炎的诊断价值. 临床肝胆病杂志. 2019(06): 1266-1269 . 本站查看
10.	李薇，任小丹，何谦，周荣幸. 血清降钙素原检测对胆道梗阻合并感染者的预测价值. 中华实验和临床感染病杂志(电子版). 2019(03): 245-249 . 百度学术
11.	张国民，韩智炜，牛兴杰，刘志慧，崔凤梅，王鑫. PCT、IL-6、CD14、CD64及TNF-α表达对肝衰竭合并医院感染患者预后的影响. 中华医院感染学杂志. 2019(16): 2450-2453 . 百度学术
12.	王鑫，张国民，牛兴杰，李萍，张冰. 肝衰竭继发感染患者外周血Toll样受体4及降钙素原、C反应蛋白变化情况分析. 现代消化及介入诊疗. 2019(10): 1084-1087+1094 . 百度学术
13.	石春霞，陈倩，王瑶，焦方舟，龚作炯. 肝功能衰竭并感染患者血清正五聚蛋白3和肝素结合蛋白及降钙素原水平变化. 中华实用诊断与治疗杂志. 2019(12): 1188-1190 . 百度学术
14.	顾静，王艳，陈丽，徐英，甘建和. HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义. 临床肝胆病杂志. 2018(04): 801-805 . 本站查看
15.	王小芳，奉万盛，周红翠，邱咏佳. 血清降钙素原、白细胞计数、C-反应蛋白与细菌血培养联合检测在感染患者中的应用价值. 中国医药导报. 2018(19): 75-78 . 百度学术
16.	沈素晶，邓超，李霭文，谭俊青. 不同化学发光检测系统测定PCT结果的相关性分析. 实验与检验医学. 2018(06): 873-875+891 . 百度学术
17.	詹金美，林欢，孙家敏. 定量检测血清降钙素原在诊断肝衰竭患者腹腔感染细菌类型中的价值. 中外医疗. 2017(28): 34-36 . 百度学术